Interpace Biosciences

Interpace Biosciences

Interpace Biosciences operates as a commercial-stage diagnostics company headquartered in Morris Plains, New Jersey, with an operational footprint spanning laboratory services and physician-office distribution. The company's core asset is its bioinformatics and molecular testing platform, which integrates genomic analysis with artificial intelligence to produce clinical decision-support tools. Unlike broad-spectrum lab companies, Interpace is concentrated on gastrointestinal and endocrine cancers, where its tests fill a specific gap between ambiguous cytology results and surgical intervention. The company's revenue derives principally from two assay lines: ThyGeNEXT and PancraGen. ThyGeNEXT assesses thyroid nodules for malignancy risk using a combination of mutation and microRNA markers, ordered by endocrinologists after an indeterminate fine-needle aspiration biopsy. PancraGen analyzes pancreatic cyst fluid to classify mucinous lesions and assess dysplasia, serving gastroenterologists managing patients with incidental pancreatic cysts found on imaging. Both tests are reimbursed through Medicare and commercial payers, tying the company's economics to established coding and coverage frameworks rather than speculative out-of-pocket markets. The clinical laboratory in Pittsburgh processes specimens from clinics across the United States. Interpace markets its tests through a small direct sales force and a network of independent distributors. The company maintains laboratory accreditations from the College of American Pathologists and Clinical Laboratory Improvement Amendments, which are prerequisites for operating a reference lab that bills federal healthcare programs. While publicly traded under the symbol IDXG, Interpace operates with a lean cost structure typical of a micro-cap life sciences firm, with periodic capital raises disclosed in SEC filings to fund operations and commercialization. Structurally, Interpace differs from most diagnostic peers by embedding a proprietary bioinformatics platform — originally branded as the Pathway Genomics platform — within its lab-developed test workflow rather than licensing third-party algorithms. This vertical integration from data pipeline to final clinical report gives the company control over its biomarker selection and evidence-generation strategy, but also concentrates technical risk in a single computational architecture.